These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 7323815)
1. Cancer clinical trials. A rational basis for use of historical controls. Gehan EA; Freireich EJ Semin Oncol; 1981 Dec; 8(4):430-6. PubMed ID: 7323815 [No Abstract] [Full Text] [Related]
2. The conduct of therapeutic trials in cancer medicine. Rudnick S; Capizzi RL Semin Oncol; 1977 Jun; 4(2):255-8. PubMed ID: 327556 [No Abstract] [Full Text] [Related]
3. Role of the FDA in cancer therapy research. Young RS Semin Oncol; 1981 Dec; 8(4):447-52. PubMed ID: 7323818 [No Abstract] [Full Text] [Related]
4. The last patient in a drug trial. Hastings Cent Rep; 1981 Dec; 11(6):21-3. PubMed ID: 7333839 [No Abstract] [Full Text] [Related]
5. European Commission considers revisions to clinical trials directive. Mason E J Natl Cancer Inst; 2010 Mar; 102(5):292-4, 297. PubMed ID: 20173121 [No Abstract] [Full Text] [Related]
6. The seamless approach to drug development in oncology. Pazdur R Clin Adv Hematol Oncol; 2016 Dec; 14(12):958-959. PubMed ID: 28212356 [No Abstract] [Full Text] [Related]
8. On the need to adjust for multiplicity in confirmatory clinical trials with master protocols. Stallard N; Todd S; Parashar D; Kimani PK; Renfro LA Ann Oncol; 2019 Apr; 30(4):506-509. PubMed ID: 30715156 [No Abstract] [Full Text] [Related]
9. Improving the evaluation of new cancer treatments: challenges and opportunities. Rothenberg ML; Carbone DP; Johnson DH Nat Rev Cancer; 2003 Apr; 3(4):303-9. PubMed ID: 12671669 [TBL] [Abstract][Full Text] [Related]
10. The role of overviews in cancer therapeutics. Simon R Stat Med; 1987; 6(3):389-96. PubMed ID: 3616291 [TBL] [Abstract][Full Text] [Related]
11. Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice. Arteaga CL; Baselga J Clin Cancer Res; 2003 May; 9(5):1579-89. PubMed ID: 12738709 [No Abstract] [Full Text] [Related]
12. Trend toward noninferiority trials may mean more difficult interpretation of trial results. Tuma RS J Natl Cancer Inst; 2007 Dec; 99(23):1746-8. PubMed ID: 18042926 [No Abstract] [Full Text] [Related]
13. European move affects academic trials research. Sinha G J Natl Cancer Inst; 2006 Aug; 98(16):1100-1. PubMed ID: 16912258 [No Abstract] [Full Text] [Related]
14. An efficient design for phase III studies of combination chemotherapies. Ellenberg SS; Eisenberger MA Cancer Treat Rep; 1985 Oct; 69(10):1147-54. PubMed ID: 4042093 [No Abstract] [Full Text] [Related]
15. Legal considerations in clinical cancer research. Robertson JA Semin Oncol; 1981 Dec; 8(4):442-6. PubMed ID: 7323817 [No Abstract] [Full Text] [Related]
16. Progression-free survival versus overall survival as the primary end point in anticancer drug trials: increasingly relevant impact of therapy following progression. Markman M Curr Oncol Rep; 2009 Jan; 11(1):1-2. PubMed ID: 19080733 [No Abstract] [Full Text] [Related]
18. Response and survival in clinical trials. Omura GA J Clin Oncol; 1986 Jun; 4(6):1013. PubMed ID: 3711954 [No Abstract] [Full Text] [Related]
19. New wine in old bottles. Bennett B; Bennett L Cancer Biother Radiopharm; 2002 Jun; 17(3):249-53. PubMed ID: 12136517 [No Abstract] [Full Text] [Related]
20. Standard Operating Procedures for clinical trials of the CESAR Central European Society for Anticancer Drug Research--EWIV. Preface. Gastl G; Dittrich C Onkologie; 2003 Oct; 26 Suppl 6():IX. PubMed ID: 23570176 [No Abstract] [Full Text] [Related] [Next] [New Search]